CGM Glucose Data Analytics Patent Landscape 2026
The CGM glucose data analytics patent space is highly concentrated, with three specialist applicants — WellDoc, the University of Virginia Patent Foundation, and Dexcom — holding the overwhelming majority of families among the top filers. Annual filing volume has plateaued near its 2021 peak, signalling a maturing field where entrenched positions are defended rather than created.
WellDoc leads a tight three-player field
WellDoc Inc holds the top-ranked position with 31 patent families, followed by the University of Virginia. Patent Foundation (17) and Dexcom Inc (14). These three organisations alone account for the bulk of activity among the top-ranked filers.
The top five filers collectively represent 88% of the hundred largest filers’ combined total — an unusually steep concentration that leaves limited room for undifferentiated new entrants at the corpus level.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | WellDoc Inc | 31 | |
| 2 | University of Virginia Patent Foundation | 17 | |
| 3 | Dexcom Inc | 14 | |
| 4 | Abbott Diabetes Care Inc | 5 | |
| 5 | MS SUPREET RUPAM | 1 | |
| 6 | GHORPADE HEM ARUN | 1 | |
| 7 | MS SONIA CHONGTHAM | 1 |
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 8 | MRS REKHA KUMARI | 1 | |
| 9 | SAHOO DIPTI MAYEE | 1 | |
| 10 | MRS BABITA RATAN PATIL | 1 | |
| 11 | SWARNANDHRA COLLEGE OF ENG & TECH AUTONOMOUS | 1 | |
| 12 | MRS KIRTI RATHEE | 1 | |
| 13 | KANDI SAMIKSHA SHRIDHAR | 1 | |
| 14 | MRS PRIYANKA NIRMAN | 1 |
WellDoc’s lead reflects a software-centric, decision-support strategy; the University of Virginia. Patent Foundation brings an academic-clinical angle with strong ties to closed-loop insulin delivery research; Dexcom contributes hardware-adjacent analytics tightly coupled to its sensor platform.
Patent families published in the most recent 18–24 months are still accumulating citations and may understate current activity; near-term counts should be read as provisional. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2021 surge reshaped the field; healthcare informatics dominates the technology mix
The filing trend reveals a sharp build-up centred on 2021, after which annual volume eased; the technology composition shows healthcare informatics as the overwhelmingly dominant class, with AI computing and clinical diagnosis as secondary themes.
Annual filing trend
Filing activity was negligible before 2019, surged to a peak of 22 families in 2021, then settled into a lower but sustained range through 2023–2025. The 2024–2026 bars reflect publication lag and should not be read as a structural decline. The multi-year window still shows positive growth (3% recent growth), consistent with a plateauing rather than retreating field.
↗ Hover for values · click a bar to ask EurekaTechnology composition
G16H (Healthcare informatics) is the dominant branch by a wide margin, reflecting the analytics and clinical-decision-support orientation of the corpus. A61B (Diagnosis and surgery) forms a meaningful secondary layer, covering sensor-side measurement methods. G06N (AI-based computing models) appears as a tertiary branch, and A61M (Devices for body fluids) is sparsely represented — making it the primary under-served adjacent branch.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Method for structuring and classification of conti…
Embodiment relate to a system for developing a model to classify continuous glucose monitoring (CGM) data. The system includes a processor and computer memory having instructions stored thereon that when executed will cause the processor to determine whether two CGM profiles match based on a similarity of shapes of the two CGM profiles, each CGM profile… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Safety tools for decision support recommendations … | 14 |
| 2 | Systems and methods for analyzing, interpreting, a… | 12 |
| 3 | Systems and methods for analyzing, interpreting, a… | 5 |
| 4 | Systems and methods for analyzing, interpreting, a… | 4 |
| 5 | Safety tools for decision support recommendations … | 4 |
| 6 | Artificial pancreas integrated CGM architectures a… | 4 |
| 7 | Method for structuring and classification of conti… | 3 |
| 8 | Systems and methods for analyzing, interpreting, a… | 2 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the patent structure means for R&D strategy
Three structural facts shape the investment calculus: the field is maturing, ownership is highly concentrated, co-filing ecosystems are absent, and the US remains the dominant jurisdiction with selective international reach.
Field at plateau — incremental differentiation required
The lifecycle stage is Maturity: annual filings have plateaued near their 2021 peak. New entrants will find the core decision-support and CGM analytics space well-covered; differentiation must come from specific technical sub-problems — such as AI-driven predictive dosing or integration with non-glucose biomarkers — rather than broad platform claims.
Lifecycle: MaturityThree-player oligopoly at the top
The top five filers account for 88% of the hundred largest filers’ combined total, with WellDoc (31 families), University of Virginia Patent Foundation (17), and Dexcom (14) forming a clear first tier. Abbott Diabetes Care Inc (5 families) is the only identifiable fourth-tier participant among established players. Below that, the long tail consists almost entirely of individual inventors and a single engineering college, none of whom hold more than one family.
High concentrationNo co-applicant activity detected in this corpus
Evidence for formal co-filing partnerships is pending — no collaboration records were identified in the dataset. The absence of cross-entity filings suggests the leading players are pursuing proprietary strategies rather than consortium-based development. This may present an opening for strategic licensing or joint-development agreements in adjacent technical areas.
Collaboration: none detectedUS-anchored with selective PCT and English-market reach
The United States is the leading jurisdiction with 25 patent records, followed by Australia (10), WIPO PCT (9), Europe EPO (7), and Canada (6). India and Japan each have 3 records; China holds just 2. The filing pattern reflects English-speaking market prioritisation and selective European protection, with limited Asian market coverage — a notable gap given the global diabetes burden.
US-led, limited AsiaGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
Co-filing pairs, ranked by the number of jointly-filed patent families.
WellDoc and University of Virginia lead by different routes
WellDoc commands the largest portfolio but its recent filing rate has declined, while the University of Virginia. Patent Foundation and Dexcom are both identified as new entrants in the recent period — suggesting the competitive front line is shifting toward academic-clinical and hardware-coupled analytics.
WellDoc Inc
With 31 patent families, WellDoc holds the largest portfolio in this corpus by a significant margin. Its technology emphasis spans G16H 50 (clinical decision support informatics), G16H 20 (medication management informatics), and A61B 5 (diagnostic measurement), consistent with its digital therapeutics positioning. However, its recent filing momentum shows a trend of ▼ –55% versus the prior period, indicating portfolio consolidation rather than active expansion.
families: 31University of Virginia Patent Foundation
Holding 17 patent families, the University of Virginia Patent Foundation is classified as a new entrant in the recent filing window — meaning its current portfolio represents a rapid, recent build-up from a near-zero prior base. Its technology focus aligns with G16H 50 (clinical decision support), A61B 5 (physiological measurement), and G16H 15 (patient health records informatics), reflecting its closed-loop insulin delivery and artificial pancreas research heritage. Dexcom Inc (14 families, also a new entrant in trend terms) represents a comparable challenger with emphasis on A61B 5 sensor-side analytics.
families: 17| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| WellDoc Inc | 9 | ▼ -55% |
| University of Virginia Patent Foundation | 16 | ▲ new entrant |
| Dexcom Inc | 5 | ▲ new entrant |
Under-served adjacent branch: devices for body fluid management
One IPC branch sits at the sparse periphery of this corpus relative to the dominant healthcare informatics classes. It is observed as under-served; whether it represents a viable entry point depends on technical fit and competitive dynamics outside this dataset.
A61M · Devices for body fluids — hardware-software integration gap
A61M (Devices for body fluids) accounts for only 4 patent records and a 3% share of the technology composition — the lowest of all four identified branches. Abbott Diabetes Care Inc is the only top-ranked applicant with recorded A61M focus (A61M 5, infusion devices), suggesting that the integration of CGM data analytics with insulin delivery hardware is largely unclaimed by the dominant software-focused players. For teams with combined sensor-hardware and analytics capability, this gap between data interpretation and physical drug delivery may represent a technically plausible adjacent area to explore.
Search this in Eureka →G06N · AI computing models — sparse relative to informatics volume
G06N (Computing based on AI models) appears in 14 patent records — notable but far below the 64 records in G16H. Given the prominence of AI-driven glucose prediction in published literature and the top-cited patents referencing artificial pancreas architectures, the relatively thin patent coverage of explicit AI/ML model claims suggests that algorithm-level innovations (e.g., reinforcement learning for closed-loop control, transformer-based glucose forecasting) may not yet be densely claimed. This is an observation of relative sparsity, not a confirmed open space; freedom-to-operate analysis is essential before any investment decision.
Search this in Eureka →How leading applicants differ across technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | G16H 50 · Healthcare informatics | G16H 20 · Healthcare informatics | A61B 5 · Diagnosis & surgery | G16H 10 · Healthcare informatics | G06N 20 · Computing based on AI models |
|---|---|---|---|---|---|
| WellDoc Inc | Strong · 31 | Strong · 28 | Strong · 19 | Moderate · 15 | Moderate · 13 |
| University of Virginia Patent Foundation | Strong · 17 | Emerging · 2 | Moderate · 7 | Moderate · 5 | Emerging · 1 |
| Dexcom Inc | Strong · 8 | Strong · 8 | Strong · 9 | Moderate · 3 | Absent |
| Abbott Diabetes Care Inc | Strong · 5 | Strong · 5 | Absent | Absent | Absent |
| GHORPADE HEM ARUN | Strong · 1 | Strong · 1 | Absent | Strong · 1 | Absent |
| KANDI SAMIKSHA SHRIDHAR | Strong · 1 | Strong · 1 | Absent | Strong · 1 | Absent |
Frequently asked questions
The corpus covers 70 patent families. This is a focused, specialist corpus rather than a broad medical-device landscape, reflecting the relative novelty of dedicated CGM data analytics as a distinct patent category.
WellDoc Inc leads with 31 patent families, more than any other single applicant. The University of Virginia Patent Foundation (17 families) and Dexcom Inc (14 families) form the second tier. Together these three account for the large majority of the top-ranked filers’ combined portfolio.
The field is classified at the Maturity stage. Annual filings peaked in 2021 and have since plateaued at a lower but sustained level. The multi-year recent-growth figure is a modest 3%, consistent with a field that has passed its rapid-growth phase.
The United States leads with 25 patent records, followed by Australia (10), WIPO PCT (9), Europe EPO (7), and Canada (6). China holds only 2 records, and Japan 3, indicating limited coverage in major Asian markets despite the global prevalence of diabetes.
G16H (Healthcare informatics) is the dominant class with 64 patent records. A61B (Diagnosis and surgery) follows with 38, G06N (AI-based computing) has 14, and A61M (Devices for body fluids) is sparsely represented at 4 records. The corpus is clearly oriented toward software and clinical decision-support rather than hardware.
No co-applicant collaboration records were identified in this dataset. The leading players appear to be filing independently, which may reflect the proprietary and competitive nature of digital therapeutics and CGM platform strategies.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.